Neurocrine Biosciences Announces Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (Valbenazine) For The Treatment Of Tardive Dyskinesia Post author:Sam Post published:March 20, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Bristol-Myers Squibb's Stock Topples as Kidney Cancer Drug Flunks Phase III Study August 15, 2017 Stanford University Clinical Geneticist Begins Presidency With The March 22, 2017 Bay Area Avinger Cuts Workforce by 33% April 10, 2017